A 52-year-old postmenopausal woman from Delhi presents with a 3-month history of a painless, hard lump in the upper outer quadrant of her right breast. On examination, the mass is 2 cm, fixed to the chest wall, with overlying skin dimpling and a positive Peau d'orange appearance. Axillary lymph nodes are palpable and hard. Mammography shows a stellate lesion with microcalcifications. Core needle biopsy reveals invasive ductal carcinoma with intermediate nuclear grade. Immunohistochemistry shows ER+, PR+, HER2−. What is the most appropriate next step in management?

Explanation

## Clinical Assessment **Key Point:** This patient has locally advanced breast cancer (LABC) — T4bN1M0 (Stage IIIB) — with skin involvement (peau d'orange, skin dimpling) and hard palpable axillary lymph nodes. The current standard of care for LABC is **neoadjuvant (primary systemic) chemotherapy** followed by surgery. ## Staging and Prognostic Factors | Feature | Finding | Significance | |---------|---------|---------------| | Tumor size | 2 cm | T2 component | | Skin involvement | Peau d'orange + dimpling | T4b (locally advanced) | | Chest wall fixation | Present | T4a/T4b | | Axillary nodes | Hard, palpable | N1 involvement | | Grade | Intermediate | Moderate aggressiveness | | ER/PR | Positive | Hormone-responsive | | HER2 | Negative | Not HER2-driven | ## Why Neoadjuvant Chemotherapy First? Per **NCCN Guidelines**, **ESMO Guidelines**, and standard oncology texts (DeVita's Cancer: Principles & Practice; Harrison's Principles of Internal Medicine): 1. **Downstaging**: Neoadjuvant chemotherapy reduces tumor burden, potentially converting an inoperable or borderline-resectable tumor to a resectable one. 2. **In vivo chemosensitivity assessment**: Pathological complete response (pCR) is a surrogate for long-term survival benefit. 3. **Systemic micrometastasis treatment**: Early systemic therapy addresses occult distant disease. 4. **Skin involvement (T4b)** and **fixed axillary nodes** are classic indications for neoadjuvant chemotherapy in LABC — this is the globally accepted standard approach. ## Management Algorithm For Stage IIIB (T4bN1M0) ER+/PR+/HER2− breast cancer: - **Step 1**: Neoadjuvant chemotherapy (e.g., anthracycline + taxane-based regimen) - **Step 2**: Re-evaluate response → Modified Radical Mastectomy (MRM) - **Step 3**: Adjuvant hormonal therapy (aromatase inhibitor preferred in postmenopausal women) - **Step 4**: Adjuvant radiotherapy to chest wall and regional nodes ## Why Option B is Incorrect Proceeding directly to **immediate MRM** without neoadjuvant chemotherapy is **not the current standard of care** for LABC with skin involvement and nodal disease. Immediate surgery in T4b disease: - Does not address systemic micrometastases early - Misses the opportunity to assess chemosensitivity - Is associated with inferior outcomes compared to neoadjuvant-first approach **High-Yield:** The NACT-first approach for LABC is supported by multiple randomized trials (NSABP B-18, B-27) and is endorsed by NCCN, ESMO, and Indian guidelines (ICMR/AIIMS protocols). Immediate surgery is reserved for early-stage operable disease. **Clinical Pearl:** In postmenopausal women with ER+/PR+ disease, after completing chemotherapy and surgery, an **aromatase inhibitor** (e.g., letrozole, anastrozole) is preferred over tamoxifen for adjuvant hormonal therapy, per ATAC and BIG 1-98 trial data (Harrison's, 21st ed.). **Key Point:** Peau d'orange (dermal lymphatic invasion) = T4b = locally advanced breast cancer → Neoadjuvant chemotherapy is the most appropriate **next step**, not immediate surgery.